Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thromboembolism 2Neoplasms 2Venous Thrombosis 1Pulmonary Embolism 1Embolism 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × edoxaban × Clear all
NCT04618913 2026-05-26

VICTORIE

Pfizer

Active not recruiting
1 enrolled
Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT02073682 2019-03-06

Cancer Venous Thromboembolism (VTE)

Daiichi Sankyo

Phase 3 Completed
1,046 enrolled 24 charts
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡